- Home
- AUTL vs KROS Comparison
AUTL vs KROS Comparison
Compare AUTL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- KROS
- Stock Information
- Founded
- AUTL 2014
- KROS 2015
- Country
- AUTL United Kingdom
- KROS United States
- Employees
- AUTL N/A
- KROS N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- KROS Health Care
- Exchange
- AUTL Nasdaq
- KROS Nasdaq
- Market Cap
- AUTL 590.8M
- KROS 589.8M
- IPO Year
- AUTL 2018
- KROS 2020
- Fundamental
- Price
- AUTL $2.37
- KROS $11.84
- Analyst Decision
- AUTL Strong Buy
- KROS Buy
- Analyst Count
- AUTL 3
- KROS 11
- Target Price
- AUTL $10.20
- KROS $45.33
- AVG Volume (30 Days)
- AUTL 1.2M
- KROS 2.1M
- Earning Date
- AUTL 03-13-2025
- KROS 02-26-2025
- Dividend Yield
- AUTL N/A
- KROS N/A
- EPS Growth
- AUTL N/A
- KROS N/A
- EPS
- AUTL N/A
- KROS N/A
- Revenue
- AUTL $10,091,000.00
- KROS $651,000.00
- Revenue This Year
- AUTL $851.83
- KROS $303.27
- Revenue Next Year
- AUTL $264.18
- KROS N/A
- P/E Ratio
- AUTL N/A
- KROS N/A
- Revenue Growth
- AUTL 82.71
- KROS 8037.50
- 52 Week Low
- AUTL $2.07
- KROS $9.78
- 52 Week High
- AUTL $7.37
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- AUTL 46.88
- KROS 24.87
- Support Level
- AUTL $2.12
- KROS $10.95
- Resistance Level
- AUTL $2.38
- KROS $11.63
- Average True Range (ATR)
- AUTL 0.13
- KROS 0.87
- MACD
- AUTL 0.02
- KROS 1.31
- Stochastic Oscillator
- AUTL 37.23
- KROS 30.60
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.